• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of pharmacy technology: jPT : official publication of the Association of Pharmacy Technicians >Safety and Efficacy of Apixaban Use in Peritoneal Dialysis: A Review of the Literature
【24h】

Safety and Efficacy of Apixaban Use in Peritoneal Dialysis: A Review of the Literature

机译：Apixaban在腹膜透析中使用的安全性和有效性：文献综述

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: To review the safety and efficacy of apixaban for the treatment of nonvalvular atrial fibrillation or venous thromboembolism in patients receiving peritoneal dialysis (PD). Data Sources: A PubMed and MEDLINE search was conducted through December 2020 using the following keywords and Medical Subject Headings (MeSH) terms alone or in various combinations: apixaban, peritoneal dialysis, continuous ambulatory peritoneal dialysis, end-stage renal disease, and hemodialysis. Study Selection and Data Extraction : English-language studies evaluating clinical outcomes pertaining to the use of apixaban in end stage renal disease (ESRD), which included patients receiving peritoneal dialysis were eligible for inclusion. Data Synthesis: Four studies were identified that met inclusion for this review, all retrospective in nature. These studies compared the safety and efficacy of apixaban with standard therapy in ESRD included patients on dialysis, with a very limited number of subjects receiving PD. In these studies, apixaban was shown to be potentially safer and more effective than warfarin. Outcomes did not differentiate between patients receiving PD or not. Conclusions: Use of apixaban in patients receiving PD may be safe and effective based on data from limited patients. Pharmacokinetics and pharmacodynamics of apixaban in the PD setting is an important question that clinicians should consider with use of this medication in the ESRD population. More studies focusing on the PD population are needed to better assess the use of apixaban in this understudied population.
机译：目的：评价阿哌沙班治疗腹膜透析（PD）患者非瓣膜性心房颤动或静脉血栓栓塞的安全性和有效性。数据来源：截至2020年12月，使用以下关键词和医学主题词（MeSH）单独或以各种组合进行PubMed和MEDLINE搜索：阿哌沙班、腹膜透析、持续非卧床腹膜透析、终末期肾病和血液透析。研究选择和数据提取：评估阿哌沙班在终末期肾病（ESRD）中使用的临床结果的英语研究，包括接受腹膜透析的患者符合纳入条件。数据综合：确定了四项研究符合本综述的要求，均为回顾性研究。这些研究比较了阿哌沙班与标准治疗ESRD的安全性和有效性，ESRD患者包括透析患者，接受PD的受试者数量非常有限。在这些研究中，阿哌沙班被证明可能比华法林更安全、更有效。结果并不能区分是否接受PD治疗的患者。结论：根据有限患者的数据，阿哌沙班用于帕金森病患者可能是安全有效的。阿哌沙班在PD组的药代动力学和药效学是临床医生在ESRD人群中考虑使用这种药物的一个重要问题。需要更多针对帕金森病人群的研究，以更好地评估阿哌沙班在这一未研究人群中的使用情况。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号